Abstract

BackgroundGay, bisexual and other men who have sex with men (MSM) are disproportionately affected by HIV in Canada. Combination antiretroviral therapy has been shown to dramatically decrease progression to AIDS, premature death and HIV transmission. However, there are no comprehensive data regarding combination antiretroviral therapy outcomes among this population. We sought to identify socio-demographic and clinical correlates of viral suppression and rebound.MethodsOur analysis included MSM participants in the Canadian Observational Cohort, a multi-site cohort of HIV-positive adults from Canada’s three most populous provinces, aged ≥18 years who first initiated combination antiretroviral therapy between 2000 and 2011. We used accelerated failure time models to identify factors predicting time to suppression (2 measures <50 copies/mL ≥30 days apart) and subsequent rebound (2 measures >200 copies/mL ≥30 days apart).ResultsOf 2,858 participants, 2,448 (86 %) achieved viral suppression in a median time of 5 months (Q1–Q3: 3–7 months). Viral suppression was significantly associated with later calendar year of antiretroviral therapy initiation, no history of injection drug use, lower baseline viral load, being on an initial regimen consisting of non-nucleoside reverse-transcriptase inhibitors, and older age. Among those who suppressed, 295 (12 %) experienced viral rebound. This was associated with earlier calendar year of antiretroviral therapy initiation, injection drug use history, younger age, higher baseline CD4 cell count, and living in British Columbia.ConclusionsFurther strategies are required to optimize combination antiretroviral therapy outcomes in men who have sex with men in Canada, specifically targeting younger MSM and those with a history of injection drug use.

Highlights

  • Gay, bisexual and other men who have sex with men (MSM) are disproportionately affected by Human immunodeficiency virus (HIV) in Canada

  • Since the implementation of combination antiretroviral therapy, people living with HIV/Acquired immune deficiency syndrome (AIDS) (PHAs) have experienced significant improvements in health outcomes and can achieve life expectancy near that of the general population [5,6,7]

  • Drawing on Canadian Observational Cohort (CANOC) data from 2000 to 2011, 3,375 male participants were identified as MSM. 214 of these participants did not have at least two viral load measurements within one year after initiating combination antiretroviral therapy (cART), and another 303 participants had less than one year of follow-up

Read more

Summary

Introduction

Bisexual and other men who have sex with men (MSM) are disproportionately affected by HIV in Canada. Bisexual and other men who have sex with men (MSM) have the highest prevalence of HIV in Canada [1]. In the first two decades of the epidemic, this disproportionate burden was characterized by premature mortality across MSM communities [3], with the estimated life expectancy of gay men in some urban environments being 8 to 20 years less than that of the general male population [4]. Since the implementation of combination antiretroviral therapy (cART), people living with HIV/AIDS (PHAs) have experienced significant improvements in health outcomes and can achieve life expectancy near that of the general population [5,6,7]. Adherent patients generally achieve viral suppression between 8 and 24 weeks after initiating treatment [10]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call